MA56001A - Formes de sel cristallin d'un inhibiteur de kinase - Google Patents

Formes de sel cristallin d'un inhibiteur de kinase

Info

Publication number
MA56001A
MA56001A MA056001A MA56001A MA56001A MA 56001 A MA56001 A MA 56001A MA 056001 A MA056001 A MA 056001A MA 56001 A MA56001 A MA 56001A MA 56001 A MA56001 A MA 56001A
Authority
MA
Morocco
Prior art keywords
kinase inhibitor
salt forms
crystalline salt
crystalline
forms
Prior art date
Application number
MA056001A
Other languages
English (en)
French (fr)
Inventor
Melanie Janelle Bevill
Frenel Demorin
Courtney S Johnson
Stephan D Parent
Khalid Shah
Sagar Shakya
Peter Wong
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA56001A publication Critical patent/MA56001A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA056001A 2019-06-03 2019-12-12 Formes de sel cristallin d'un inhibiteur de kinase MA56001A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03

Publications (1)

Publication Number Publication Date
MA56001A true MA56001A (fr) 2022-04-06

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056001A MA56001A (fr) 2019-06-03 2019-12-12 Formes de sel cristallin d'un inhibiteur de kinase

Country Status (22)

Country Link
US (1) US20230052703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976587B1 (cg-RX-API-DMAC7.html)
JP (1) JP7579281B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826380B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939503B (cg-RX-API-DMAC7.html)
AU (1) AU2019449809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139148A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003205A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017343A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210616A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000236A (cg-RX-API-DMAC7.html)
ES (1) ES3008963T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247655B (cg-RX-API-DMAC7.html)
IL (1) IL288484A (cg-RX-API-DMAC7.html)
MA (1) MA56001A (cg-RX-API-DMAC7.html)
MX (1) MX2021014773A (cg-RX-API-DMAC7.html)
PE (1) PE20220962A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553020A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111978VA (cg-RX-API-DMAC7.html)
WO (1) WO2020247019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108034B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
SG187064A1 (en) * 2010-07-14 2013-02-28 Zhejiang Beta Pharma Inc NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
GEAP202415849A (en) 2024-03-11
CO2021017343A2 (es) 2022-01-17
GEP20247655B (en) 2024-08-26
BR112021024300A2 (pt) 2022-01-11
CN113939503B (zh) 2024-05-07
SG11202111978VA (en) 2021-11-29
WO2020247019A1 (en) 2020-12-10
KR20220016117A (ko) 2022-02-08
CA3139148A1 (en) 2020-12-10
MX2021014773A (es) 2022-01-18
EP3976587B1 (en) 2024-12-04
CL2021003205A1 (es) 2022-09-30
EP3976587A1 (en) 2022-04-06
JP2022535072A (ja) 2022-08-04
CR20210616A (es) 2022-03-22
PH12021553020A1 (en) 2023-08-23
KR102826380B1 (ko) 2025-06-26
ES3008963T3 (en) 2025-03-25
DOP2021000236A (es) 2022-04-18
US20230052703A1 (en) 2023-02-16
PE20220962A1 (es) 2022-06-10
CN113939503A (zh) 2022-01-14
AU2019449809A1 (en) 2021-12-16
ZA202108034B (en) 2025-02-26
AU2019449809B2 (en) 2026-02-05
IL288484A (en) 2022-01-01
EP3976587C0 (en) 2024-12-04
JP7579281B2 (ja) 2024-11-07

Similar Documents

Publication Publication Date Title
EP3924352A4 (en) CRYSTALLINE FORMS OF AN RSK INHIBITOR
EP3947361A4 (en) SALT AND CRYSTAL FORM OF A FAK INHIBITOR
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
EP3870178A4 (en) Crystalline forms of mnk inhibitors
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
EP3619208C0 (en) CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND
EP3472168A4 (en) CRYSTALLINE FORMS OF A TRIAZOLOPYRIMIDINE COMPOUND
IL288484A (en) Crystalline salt forms of a kinase inhibitor
DK4055021T3 (da) Heterocykliske rip1-inhiberende forbindelser
EP3807279A4 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
MA51082A (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
IL289929A (en) Crystal forms of cd73 inhibitor
EP3829551A4 (en) CRYSTALLINE EPINEPHRIN MALONATE SALT
EP3897660A4 (en) NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND
EP3873463A4 (en) CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR
MA54638A (fr) Formes cristallines d'un stimulateur de sgc
SG11202102110PA (en) Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
EP4019496A4 (en) SALT AND CRYSTAL FORM OF A COMPOUND WITH AGONISTIC ACTION ON S1P5 RECEPTOR
MA53162A (fr) Sel de xinafoate d'un composé inhibiteur de jak
EP3996707A4 (en) CRYSTALLINE FORMS OF PLASMACALLICREIN INHIBITORS
EP3847175A4 (en) CRYSTALLINE FORMS OF AN INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE (PI3K)
EP3896063A4 (en) SALT INES SYK INHIBITORS AND CRYSTALLINE FORM THEREOF